The pharmacological management of depression
Open accessThe DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Abstract
Depressive disorders are common, recurrent, and chronic, and require treatment A review of the symptom picture and current drug targets demonstrates the need for accurate assessment of depression severity, including suicidality. The initial focus of treatment is rapid resolution of symptoms during an acute phase, followed by continuation. Maintenance treatment is indicated if the risk of recurrence is high. The range of available medications is considerable and the benefit/risk ratio is acceptable. Depression is diagnosable across the life span and treatable at every age (although recent disagreement has arisen with regard to young patients). Comorbidity, both psychiatric and medical, need to be assessed, as does the possible presence of two subtypes of depression (psychotic and bipolar) often requiring different interventions. It is expected that the next generation of antidepressants would be associated with more specific disease and outcome biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive Therapy for Depression: (675542012-001)
(2012) · PsycEXTRA Dataset · doi:10.1037/e675542012-001 · Cited by 9,663
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988 · cited 1×
“2 million adults) in a recent survey.(1) According to the World Health Organization’s Global Burden of Disease Report,(2) major depression was the fourth leading cause of disease burden worldwide in 1990.”
Background(1996) · Cited by 6,884
(1984) · The Lancet · doi:10.1016/s0140-6736(84)92810-1 · Cited by 2,925
Depression Following Myocardial Infarction: Impact on 6-Month Survival
Frasure-Smith, N. (1993) · JAMA · doi:10.1001/jama.1993.03510150053029 · Cited by 1,939
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414
Interpersonal Psychotherapy Of Depression
Klerman, G. L. (1984) · Medical Entomology and Zoology · Cited by 1,315
Three-Year Outcomes for Maintenance Therapies in Recurrent Depression
Frank, E. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810240013002 · Cited by 1,297
Self-citationThe cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 1×
“Most recently, attention has moved from intrasynaptic changes in neurotransmitter levels to changes in intracellular signaling pathways.(9) In an important review, Manji and colleagues(9) raise the possibility that depression may be associated with impairments in signaling pathways that are considered important for th…”
BackgroundMood disorders and allostatic load
McEwen, B. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00177-x · Cited by 1,135 · cited 1×
“In turn,McEwen’s concept of “allostatic load”may be incorporated into how recurrent depression leads to structural and functional central nervous system (CNS) impairment.(10)”
BackgroundSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076 · cited 1×
“Clearer guidelines for treatment augmentation and switching should be derived from the ongoing multisite NIMH contract, Sequenced Treatment Alternative to Relieve Depression (STAR*D).(83) This large multicenter trial (ultimately enrolling more than 4000 patients nationwide) is prospectively evaluating alternative anti…”
BackgroundSelf-citationCalabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
St John's wort for depression—an overview and meta-analysis of randomised clinical trials
Linde, K., Ramirez, G., Mulrow, C. D., Pauls, A., Weidenhammer, W., & Melchart, D. (1996) · BMJ · doi:10.1136/bmj.313.7052.253 · Cited by 989
Extending Indications for Long-Term Pharmacotherapy: Opportunities and Challenges
Kane, J. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.1 · Cited by 987
Emslie, G. J. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230069010 · Cited by 985 · cited 1×
“The SSRIs are the only class of medications with some level of proven efficacy in pediatric unipolar depression.(49,101,102) Practitioners are compelled to treat depressed bipolar children and adolescents using the SSRI because the illness is so severe; however, the SSRI sometimes worsen the cyclicity of the disorder.”
BackgroundRelapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Self-citationTohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908 · cited 1×
“Recently, efforts to combine an SSRI with an atypical antipsychotic(95) have shown promising results in bipolar depression.(96) A number of atypical antipsychotic drugs are also showing some degree of antidepressant effect, perhaps similar to that of lithium.”
BackgroundRemission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801 · cited 1×
“Nemeroff, personal communication).(28,29) The antidepressant market remains a highly competitive one, with a number of pharmaceutical companies introducing compounds that they hope will prove to have faster onset of action, produce a more complete remission, and reduce side-effect burden, especially weight gain and se…”
BackgroundReynolds III, C. F., Frank, E., Perel, J. M., Imber, S. D., Cornes, C., Miller, M. D., Mazumdar, S., Houck, P. R., Dew, M. A., Stack, J. A., et al. (1999) · JAMA · doi:10.1001/jama.281.1.39 · Cited by 659 · cited 1×
“While this report is not focused on psychotherapy for treatment of depression, it is noteworthy that the combination of antidepressants and specific targeted psychotherapy (interpersonal psychotherapy) has been conducted successfully in long-term trials with some suggestion in the elderly that combination treatment wa…”
ResultSelf-citationEffects of SSRIs on Sexual Function: A Critical Review
Rosen, R. C., Lane, R. M., & Menza, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00013 · Cited by 650
KELLER, M. B., RYAN, N. D., STROBER, M., KLEIN, R. G., KUTCHER, S. P., BIRMAHER, B., HAGINO, O. R., KOPLEWICZ, H., CARLSON, G. A., CLARKE, G. N., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00010 · Cited by 641
Calabrese, J. R., Bowden, C. L., Sachs, G., Yatham, L. N., Behnke, K., Mehtonen, O.-P., Montgomery, P., Ascher, J., Paska, W., Earl, N., et al. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0906 · Cited by 635 · cited 1×
“One hierarchy of mood stabilizer options is: (i) lithium carbonate; (ii) divalproex; (iii) olanzapine (now FDA-approved for mania and maintenance in bipolar disorder); and (iv) lamotrigine (FDA-approved for maintenance in bipolar disorder).(95,97,98) The particular medication is chosen on the basis of the patient’s hi…”
BackgroundEven minimal symptoms of depression increase mortality risk after acute myocardial infarction
Bush, D. E., Ziegelstein, R. C., Tayback, M., Richter, D., Stevens, S., Zahalsky, H., & Fauerbach, J. A. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01675-7 · Cited by 620
Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00138-4 · Cited by 590
Comprehensive Guide to Interpersonal Psychotherapy
(2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.474 · Cited by 584
EMSLIE, G. J., HEILIGENSTEIN, J. H., WAGNER, K. D., HOOG, S. L., ERNEST, D. E., BROWN, E., NILSSON, M., & JACOBSON, J. G. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200210000-00010 · Cited by 581 · cited 1×
“The SSRIs are the only class of medications with some level of proven efficacy in pediatric unipolar depression.(49,101,102) Practitioners are compelled to treat depressed bipolar children and adolescents using the SSRI because the illness is so severe; however, the SSRI sometimes worsen the cyclicity of the disorder.”
BackgroundLifetime risk of suicide for affective disorder, alcoholism and schizophrenia
Inskip, H., Harris, C., & Barraclough, B. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.172.1.35 · Cited by 579
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574 · cited 1×
“While nausea, sedation, appetite change, and sexual dysfunction seem approximately similar for the SSRI class, claims for reduced adverse effects on sexual functioning have been made for fluvoxamine (only approved by the FDA for obsessive-compulsive disorder),(42) as have claims for reduced discontinuation effects for…”
BackgroundPrien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Preclinical models: status of basic research in depression
Nestler, E. J., Gould, E., & Manji, H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01405-1 · Cited by 558
Smith, D., Dempster, C., Glanville, J., Freemantle, N., & Anderson, I. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.396 · Cited by 538 · cited 1×
“Nemeroff, personal communication).(28,29) The antidepressant market remains a highly competitive one, with a number of pharmaceutical companies introducing compounds that they hope will prove to have faster onset of action, produce a more complete remission, and reduce side-effect burden, especially weight gain and se…”
BackgroundTreatment-Resistant Depression
(2015) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-642-36172-2_200431 · Cited by 488
Hypericum Depression Trial Study Group (2002) · JAMA · doi:10.1001/jama.287.14.1807 · Cited by 480
(2002) · Cited by 479
Self-citationSchulberg, H. C., Katon, W., Simon, G. E., & Rush, A. J. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1121 · Cited by 459 · cited 1×
“Clinical guidelines generally recommend that treatment should be continued for at least 6 months following remission of acute symptoms.(114,115) However, because of the recurrent nature of depressive disorder, a question is S t a t e o f t h e a r t”
BackgroundTreatment resistant depression: methodological overview and operational criteria
Souery, D., Amsterdam, J., de Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O., Racagni, G., Zohar, J., & Mendlewicz, J. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00004-2 · Cited by 444 · cited 1×
“Clinical trials have demonstrated that 30% to 40% of depressed patients fail to respond to firstline antidepressant treatment despite adequate adherence, dose, and duration,(76,77) 60% to 70% fail to achieve a complete remission of symptoms,(78) up to 20% have not recovered 2 years after initiation of treatment,(79,80…”
BackgroundBiobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS)
Ahern, D. K., Gorkin, L., Anderson, J. L., Tierney, C., Hallstrom, A., Ewart, C., Capone, R. J., Schron, E., Kornfeld, D., Herd, J. A., et al. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90736-k · Cited by 432
Williams, J. W., Mulrow, C. D., Chiquette, E., Noël, P. H., Aguilar, C., & Cornell, J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00011 · Cited by 423 · cited 1×
“Despite a number of meta-analyses of efficacy showing no differences between TCAs and SSRIs in ambulatory studies, the more favorable adverse effect profile (including a virtual absence of overdosage lethality), ease of administration, and acceptance by physicians across specialties have led to the emergence of the SS…”
BackgroundNemeroff, C. B., Evans, D. L., Gyulai, L., Sachs, G. S., Bowden, C. L., Gergel, I. P., Oakes, R., & Pitts, C. D. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.906 · Cited by 407
Robinson, R. G., Schultz, S. K., Castillo, C., Kopel, T., Kosier, J. T., Newman, R. M., Curdue, K., Petracca, G., & Starkstein, S. E. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.3.351 · Cited by 384
Effectiveness of St John's Wort in Major Depression: A Randomized Controlled Trial
Shelton, R. C., Keller, M. B., Gelenberg, A., Dunner, D. L., Hirschfeld, R., Thase, M. E., Russell, J., Lydiard, R. B., Crits-Christoph, P., Gallop, R., et al. (2001) · JAMA · doi:10.1001/jama.285.15.1978 · Cited by 382
Waldinger, M. D., Hengeveld, M. W., Zwinderman, A. H., & Olivier, B. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00004 · Cited by 380
Nyth, A. L., & Gottfries, C. G. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.157.6.894 · Cited by 379 · cited 1×
“Although most data are supportive of SSRIs as a class in the treatment of geriatric depression, experts favor the use of citalopram or sertraline over fluvoxamine and fluoxetine(54,70) because of their favorable pharmacokinetic profiles, a lower potential for clinically significant drug–drug interaction, and data sugg…”
ResultAndersen, G., Vestergaard, K., & Lauritzen, L. (1994) · Stroke · doi:10.1161/01.str.25.6.1099 · Cited by 378
Managing Depression in Medical Outpatients
Whooley, M. A., & Simon, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432607 · Cited by 375 · cited 1×
“If the plan includes medication, it must involve the choice of an appropriate drug prescribed at an adequate dosage and for a sufficient duration, with attention to treatment adherence by patient and family members or caretakers, if necessary.(11) Recognition and treatment of depression in the context of an ongoing me…”
BackgroundPractice guideline for the treatment of patients with bipolar disorder (revision).
(2002) · PubMed · Cited by 375
Pham, L., Shaer, A. J., & Marnejon, T. (2013) · Case Reports in Nephrology and Dialysis · doi:10.1159/000350910 · Cited by 372
Tranylcypromine versus imipramine in anergic bipolar depression
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.7.910 · Cited by 360
The pharmacological treatment of delusional depression
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.4.430 · Cited by 357
An open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Wagner, K. D., Robb, A. S., Findling, R. L., Jin, J., Gutierrez, M. M., & Heydorn, W. E. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.1079 · Cited by 308
The Mood Spectrum in Unipolar and Bipolar Disorder: Arguments for a Unitary Approach
Cassano, G. B., Rucci, P., Frank, E., Fagiolini, A., Dell’Osso, L., Shear, M. K., & Kupfer, D. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.7.1264 · Cited by 302
Self-citationMAOIs in the Contemporary Treatment of Depression
Thase, M. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00058-8 · Cited by 301 · cited 1×
“The second original class of drugs, the monoamine oxidase inhibitors (MAOIs), have never been widely prescribed because of real (and sometimes exaggerated) concerns about safety, despite their established efficacy in certain subtypes, especially atypical and bipolar depression.(24,25) A majority of the newer compounds…”
BackgroundLiu, B. A., Mittmann, N., Knowles, S. R., & Shear, N. H. (1996) · Europe PMC (PubMed Central) · Cited by 290
Comorbidity of depression with other medical diseases in the elderly
Krishnan, K. R. R., Delong, M., Kraemer, H., Carney, R., Spiegel, D., Gordon, C., McDonald, W., Dew, M. A., Alexopoulos, G., Buckwalter, K., et al. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01472-5 · Cited by 290
Prevalence of Depressive Episodes With Psychotic Features in the General Population
Ohayon, M. M., & Schatzberg, A. F. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1855 · Cited by 290
Recovery from depression, work productivity, and health care costs among primary care patients
Simon, G. E., Revicki, D., Heiligenstein, J., Grothaus, L., VonKorff, M., Katon, W. J., & Hylan, T. R. (2000) · General Hospital Psychiatry · doi:10.1016/s0163-8343(00)00072-4 · Cited by 267
MacGillivray, S., Arroll, B., Hatcher, S., Ogston, S., Reid, I., Sullivan, F., Williams, B., & Crombie, I. (2003) · BMJ · doi:10.1136/bmj.326.7397.1014 · Cited by 265 · cited 1×
“Despite a number of meta-analyses of efficacy showing no differences between TCAs and SSRIs in ambulatory studies, the more favorable adverse effect profile (including a virtual absence of overdosage lethality), ease of administration, and acceptance by physicians across specialties have led to the emergence of the SS…”
BackgroundRelapse in Major Depressive Disorder: Analysis With the Life Table
Keller, M. B. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290080031005 · Cited by 260
Nyth, A. L., Gottfries, C. G., Lyby, K., Smedegaard‐Andersen, L., Gylding‐Sabroe, J., Kristensen, M., Refsum, H. ‐., Öfsti, E., Eriksson, S., & Syversen, S. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb03242.x · Cited by 258 · cited 1×
“Although most data are supportive of SSRIs as a class in the treatment of geriatric depression, experts favor the use of citalopram or sertraline over fluvoxamine and fluoxetine(54,70) because of their favorable pharmacokinetic profiles, a lower potential for clinically significant drug–drug interaction, and data sugg…”
ResultDelusional and nondelusional unipolar depression: further evidence for distinct subtypes
(1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.3.328 · Cited by 255
Peretti, S., Judge, R., & Hindmarch, I. (2000) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2000.tb10944.x · Cited by 236
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214
(1990) · PubMed · Cited by 199
Lecrubier, Y., Clerc, G., Didi, R., & Kieser, M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.8.1361 · Cited by 192
Roose, S. P., Sackeim, H. A., Krishnan, K. R. R., Pollock, B. G., Alexopoulos, G., Lavretsky, H., Katz, I. R., Hakkarainen, H., & Old-Old Depression Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.2050 · Cited by 191 · cited 1×
“years old) with depression, active medication (citalopram) was no more effective than placebo, except for patients with high levels of baseline severity.(74) Among the TCAs, where cardiac monitoring is recommended, nortriptyline is the most frequently used agent in the elderly, probably because it is considered the le…”
BackgroundPsychiatric disorders in older primary care patients
Lyness, J. M., Caine, E. D., King, D. A., Cox, C., & Yoediono, Z. (1999) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1999.00326.x · Cited by 186
Keller, M. B. (1998) · JAMA · doi:10.1001/jama.280.19.1665 · Cited by 184 · cited 1×
“Furthermore, studies on long-term treatment of chronic depression (major depression with an episode lasting greater than 2 years) with the TCAs, desipramine and imipramine, and the SSRI, sertraline, have demonstrated efficacy in chronic depression.(121,122) While this report is not focused on psychotherapy for treatme…”
BackgroundFrank, E., Cyranowski, J. M., Rucci, P., Shear, M. K., Fagiolini, A., Thase, M. E., Cassano, G. B., Grochocinski, V. J., Kostelnik, B., & Kupfer, D. J. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.905 · Cited by 184 · cited 1×
“These components follow the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) nosology for mood disorders, but recently there has been considerable interest in assessing not only current symptoms, but also “softer” or spectrum features, which may present lifetime signs of…”
BackgroundSelf-citationOccurrence and Course of Suicidality During Short-term Treatment of Late-Life Depression
Szanto, K., Mulsant, B. H., Houck, P., Dew, M. A., & Reynolds, C. F. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.610 · Cited by 179 · cited 1×
“Depressed patients with suicidal ideation often take longer to respond to treatment, thus necessitating a longer period of vigilance on the clinician’s part.(16) Due diligence includes both frequent assessments of suicidal ideation and hopelessness, aggressive treatment of the depression, and creation of a safety net…”
BackgroundQuitkin, F. M., Stewart, J. W., Mcgrath, P. J., Tricamo, E., Rabkin, J. G., Ocepek-Welikson, K., Nunes, E., Harrison, W., & Klein, D. F. (1993) · British Journal of Psychiatry · doi:10.1192/s0007125000292465 · Cited by 176 · cited 1×
“The second original class of drugs, the monoamine oxidase inhibitors (MAOIs), have never been widely prescribed because of real (and sometimes exaggerated) concerns about safety, despite their established efficacy in certain subtypes, especially atypical and bipolar depression.(24,25) A majority of the newer compounds…”
BackgroundRelation between myocardial infarction, depression, hostility, and death
Kaufmann, M. W., Fitzgibbons, J. P., Sussman, E. J., Reed, J. F., Einfalt, J. M., Rodgers, J. K., & Fricchione, G. L. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70159-6 · Cited by 175
Schneider, L. S., Nelson, J. C., Clary, C. M., Newhouse, P., Krishnan, K. R. R., Shiovitz, T., Weihs, K., & the Sertraline Elderly Depression Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1277 · Cited by 166 · cited 1×
“One placebo-controlled study with sertraline in elderly outpatients with major depression treated in both psychiatric and primary care settings further supports use of SSRIs in geriatric depression.(73) In the “old-old” population (≥75 S t a t e o f t h e a r t”
A Double-Blind Comparison of Sertraline and Fluoxetine in Depressed Elderly Outpatients
Newhouse, P. A., Krishnan, K. R. R., Doraiswamy, P. M., Richter, E. M., Batzar, E. D., & Clary, C. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0804 · Cited by 163 · cited 1×
“Although most data are supportive of SSRIs as a class in the treatment of geriatric depression, experts favor the use of citalopram or sertraline over fluvoxamine and fluoxetine(54,70) because of their favorable pharmacokinetic profiles, a lower potential for clinically significant drug–drug interaction, and data sugg…”
ResultTaragano, F. E., Lyketsos, C. G., Mangone, C. A., Allegri, R. F., & Comesaña-Diaz, E. (1997) · Psychosomatics · doi:10.1016/s0033-3182(97)71461-0 · Cited by 162
Antidepressant discontinuation syndromes
Haddad, P. M., Anderson, I., & Rosenbaum, J. (2004) · Adverse Syndromes and Psychiatric Drugs · doi:10.1093/med/9780198527480.003.0010 · Cited by 160
Psychotic (delusional) depression: a meta-analysis of physical treatments
Parker, G., Roy, K., Hadzi-Pavlovic, D., & Pedic, F. (1992) · Journal of Affective Disorders · doi:10.1016/0165-0327(92)90056-c · Cited by 158
Bipolar depression: pharmacotherapy and related therapeutic strategies
Thase, M. E., & Sachs, G. S. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00980-x · Cited by 158
Is treatment-resistant depression a unique subtype of depression?
Fagiolini, A. M., & Kupfer, D. J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01670-0 · Cited by 157 · cited 1×
“Some depressive conditions, including psychotic depression, bipolar depression, and depression with psychiatric or medical comorbidity, have been associated with poor outcome and/or a higher degree of resistance to specific types of treatment or to treatment in general.(82) Successful treatment of major depression may…”
BackgroundSelf-citationThe relationship between anxiety disorders and age
Krasucki, C., Howard, R., & Mann, A. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199802)13:2<79::aid-gps739>3.0.co;2-g · Cited by 156
Relapse of depression in primary care: Rate and clinical predictors
Lin, E. H. B. (1998) · Archives of Family Medicine · doi:10.1001/archfami.7.5.443 · Cited by 152 · cited 2×
“The goals of the acute phase are to achieve remission (resolution of all symptoms) and restore functioning (Table III).(17,18) During this period, continued follow-up visits are essential.”
BackgroundKatona, C. L. E., Hunter, B. N., & Bray, J. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199802)13:2<100::aid-gps738>3.0.co;2-j · Cited by 147
Brent, D. A., & Birmaher, B. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp012249 · Cited by 145
Pharmacotherapy of Depression in Older Patients: A Summary of the Expert Consensus Guidelines
ALEXOPOULOS, G. S., KATZ, I. R., REYNOLDS, C. F., CARPENTER, D., DOCHERTY, J. P., & ROSS, R. W. (2001) · Journal of Psychiatric Practice · doi:10.1097/00131746-200111000-00003 · Cited by 133
Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm
Mulsant, B. H., Alexopoulos, G. S., Reynolds, C. F., Katz, I. R., Abrams, R., Oslin, D., Schulberg, H. C., & the PROSPECT Study Group (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.465 · Cited by 131
The American Psychiatric Publishing Textbook of Geriatric Psychiatry
Steffens, D. C., Blazer, D. G., & Thakur, M. E. (2015) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615370054 · Cited by 128
To Your Health: How to Understand What Research Tells Us about Risk
KRAEMER, H. C., Lowe, K. K., & Kupfer, D. J. (2005) · Cited by 128
Self-citationMaintenance Therapy for Chronic Depression: A Controlled Clinical Trial of Desipramine
Kocsis, J. H. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830090013002 · Cited by 121 · cited 1×
“Furthermore, studies on long-term treatment of chronic depression (major depression with an episode lasting greater than 2 years) with the TCAs, desipramine and imipramine, and the SSRI, sertraline, have demonstrated efficacy in chronic depression.(121,122) While this report is not focused on psychotherapy for treatme…”
Background(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.6.929 · Cited by 115 · cited 1×
“Therapeutic interest in psychostimulants has led to studies suggesting that methylphenidate is generally well tolerated and modestly efficacious for medically burdened depressed elders, but should only be used in the short term.(30) It is also appropriate to comment on the current status of herbal remedies for depress…”
BackgroundChallenges in the treatment of depression with psychotic features
Rothschild, A. J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01747-x · Cited by 112 · cited 1×
“While ECT is efficacious (for psychotic depression), it has many drawbacks including the requirement that the treatment must be administered under anesthesia in a hospital setting or a similarly equipped ambulatory setting.(91)”
BackgroundTexas Medication Algorithm Project, Phase 3 (TMAP-3): Rationale and Study Design
Rush, A. J., Crismon, M. L., Kashner, T. M., Toprac, M. G., Carmody, T. J., Trivedi, M. H., Suppes, T., Miller, A. L., Biggs, M. M., Shores-Wilson, K., et al. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0402 · Cited by 108 · cited 3×
“The goals of the acute phase are to achieve remission (resolution of all symptoms) and restore functioning (Table III).(17,18) During this period, continued follow-up visits are essential.”
BackgroundMethodGill, H. S., DeVane, C. L., & Risch, S. C. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00007 · Cited by 107
Klysner, R., Bent-Hansen, J., Hansen, H. L., Lunde, M., Pleidrup, E., Poulsen, D. L., Andersen, M., & Petersen, H. E. H. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.1.29 · Cited by 106
Depression—A Cardiac Risk Factor in Search of a Treatment
Frasure-Smith, N. (2003) · JAMA · doi:10.1001/jama.289.23.3171 · Cited by 100 · cited 1×
“Recent trials with SSRIs are pointing to these medications as safe and effective treatment for recurrent depression with recent MI or unstable angina, although a beneficial effect on the underlying cardiac disease has not been found consistently in studies to date.(112,113) It is likely that similar findings will emer…”
Primary Unipolar Depression and the Prognostic Importance of Delusions
Coryell, W. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290100051008 · Cited by 99
Developing novel treatments for mood disorders: accelerating discovery
Tamminga, C. A., Nemeroff, C. B., Blakely, R., Brady, L. S., Carter, C. S., Davis, K. L., Dingledine, R. J., Gorman, J. M., Grigoriadis, D. E., Henderson, D. C., et al. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01470-1 · Cited by 94 · cited 1×
“Other novel treatment strategies are also in the pipeline.(8) Most recently, attention has moved from intrasynaptic changes in neurotransmitter levels to changes in intracellular signaling pathways.”
BackgroundSymptomatology of Late-Life Minor Depression Among Primary Care Patients
Oxman, T. E., Barrett, J. E., Barrett, J., & Gerber, P. (1990) · Psychosomatics · doi:10.1016/s0033-3182(90)72191-3 · Cited by 94
Consumption of Alcohol, Nicotine, and Caffeine Among Depressed Outpatients
Worthington, J. J., Fava, M., Agustin, C., Alpert, J. E., Nierenberg, A. A., Pava, J. A., & Rosenbaum, J. F. (1996) · Psychosomatics · doi:10.1016/s0033-3182(96)71515-3 · Cited by 92 · cited 1×
“In fact, even moderate use of psychoactive substances such as alcohol can have a negative effect on the outcome of treatment for major depression and should be discouraged until the depression is fully remitted.(105) The frequent association of substance abuse with other comorbid disorders (eg, antisocial personality…”
BackgroundTo Your Health: How to Understand What Research Tells Us About Risk
Kraemer, H. C., Lowe, K. K., & Kupfer, D. J. (2005) · doi:10.1093/oso/9780195178708.001.0001 · Cited by 92
Self-citationSelective Serotonin Reuptake Inhibitors for Late-Life Depression: A Comparative Review
Solai, L. K., Mulsant, B. H., & Pollock, B. G. (2001) · Drugs & Aging · doi:10.2165/00002512-200118050-00006 · Cited by 90
Hochstrasser, B., Isaksen, P. M., Koponen, H., Lauritzen, L., Mahnert, F. A., Rouillon, F., Wade, A. G., Andersen, M., Pedersen, S. F., De Swart, J. C. G., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.4.304 · Cited by 85
Best clinical practice: guidelines for managing major depression in primary medical care.
Schulberg, H. C., Katon, W. J., Simon, G. E., & Rush, A. J. (1999) · PubMed · Cited by 84
Lépine, J.-P., Caillard, V., Bisserbe, J.-C., Troy, S., Hotton, J.-M., Boyer, P., & For the PREVERS Investigators (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.836 · Cited by 83
Adverse reactions of antidepressants in elderly patients.
Pollock, B. G. (1999) · PubMed · Cited by 79
Sertraline Pharmacokinetics and Dynamics in Adolescents
AXELSON, D. A., PEREL, J. M., BIRMAHER, B., RUDOLPH, G. R., NUSS, S., BRIDGE, J., & BRENT, D. A. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00003 · Cited by 70 · cited 1×
“Because children and adolescents metabolize SSRI more rapidly than adults, they often require doses above the equivalent of 20 mg fluoxetine to attain a clinical response.(52) The large National Institute of Mental Health (NIMH) multicenter contract, Treatment for Adolescents With Depression Study (TADS),(53) for the…”
BackgroundFluvoxamine in the treatment of demented elderly patients: a double‐blind, placebo‐controlled study
Olafsson, K., Jørgensen, S., Jensen, H. V., Bille, A., Arup, P., & Andersen, J. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb03211.x · Cited by 68
Haustein, K.-O., Haffner, S., & Woodcock, B. G. (2002) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40404 · Cited by 65 · cited 1×
“Tobacco smoking can induce CYP enzyme changes affecting blood levels of various antidepressants, as well as complicate drug management when smoking cessation occurs.(44) S t a t e o f t h e a r t”
BackgroundThird-Generation Antidepressants: Do They Offer Advantages Over the SSRIs?
Olver, J. S., Burrows, G. D., & Norman, T. R. (2001) · CNS Drugs · doi:10.2165/00023210-200115120-00004 · Cited by 63
Treatment-Resistant Depression: Progress and Limitations
O’Reardon, J. P., & Amsterdam, J. D. (1998) · Psychiatric Annals · doi:10.3928/0048-5713-19981101-08 · Cited by 61
Placebo in Clinical Trials for Depression: Complexity and Necessity
Kupfer, D. J., & Frank, E. (2002) · JAMA · doi:10.1001/jama.287.14.1853 · Cited by 58
Self-citationFluoxetine in the Prevention of Depressive Recurrences: A Double-Blind Study
Gilaberte, I., Montejo, A. L., de la Gandara, J., Perez-Sola, V., Bernardo, M., Massana, J., Martin-Santos, R., Santiso, A., Noguera, R., Casais, L., et al. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00009 · Cited by 58
Cognitive and Psychomotor Effects of Paroxetine and Sertraline on Healthy Elderly Volunteers
Furlan, P., Kallan, M. J., Have, T. T., Pollock, B. G., Katz, I. R., & Lucki, I. (2001) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200111000-00012 · Cited by 54 · cited 1×
“Although most data are supportive of SSRIs as a class in the treatment of geriatric depression, experts favor the use of citalopram or sertraline over fluvoxamine and fluoxetine(54,70) because of their favorable pharmacokinetic profiles, a lower potential for clinically significant drug–drug interaction, and data sugg…”
ResultConsiderations for the use of antidepressants in patients with cardiovascular disease
Roose, S. P. (2000) · American Heart Journal · doi:10.1067/mhj.2000.109977 · Cited by 54
Bipolar Disorder in the Elderly
Umapathy, C., Mulsant, B. H., & Pollock, B. G. (2000) · Psychiatric Annals · doi:10.3928/0048-5713-20000701-08 · Cited by 52
Treatment of depression in the elderly: effect of physical illness on response
Evans, M., Hammond, M., Wilson, K., Lye, M., & Copeland, J. (1997) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199712)12:12<1189::aid-gps715>3.0.co;2-z · Cited by 43
Treatment of depression in comorbid medical illness
Goodnick, P. J., & Hernandez, M. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.7.1367 · Cited by 43
THE MANAGEMENT OF TREATMENT RESISTANCE IN DEPRESSED PATIENTS WITH SUBSTANCE USE DISORDERS
Nunes, E. V., Deliyannides, D. A., Donovan, S. J., & McGrath, P. J. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70290-2 · Cited by 41 · cited 1×
“Comorbidity of substance and alcohol abuse with depression is generally associated with a worse prognosis.(104) Several symptoms of alcohol and substance abuse, such as sleep disturbance, irritability, and dysphoria, contribute to this outcome.”
BackgroundUse of SSRIs in “Very Old” Depressed Nursing Home Residents
Trappler, B., & Cohen, C. I. (1998) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199802000-00011 · Cited by 39
Management of bipolar disorder in children and adolescents.
Wagner, K. D. (2002) · PubMed · Cited by 37
Arranz, F. J., & Ros, S. (1997) · Journal of Affective Disorders · doi:10.1016/s0165-0327(97)00092-x · Cited by 14
Medical disorders and treatment-resistant depression
O’Reardon, J. P., & Amsterdam, J. D. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511666421.019 · Cited by 7
The challenges of pharmacotherapy of bipolar depression
Thase, M. E., & Sachs, G. S. (2002) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(02)00045-2 · Cited by 5
Olanzapine-fluoxetine combination for psychotic major depression
Dubé, S., Rothschild, A. J., Andersen, S. W., Sanger, T. M., Clemow, D. B., Tohen, M. F., & Tollefson, G. D. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)80147-x · Cited by 5 · cited 1×
“Although SSRIs alone have not been used routinely to treat psychotic depression, the use of an SSRI and an atypical antipsychotic has shown efficacy greater than an SSRI alone.(89) C-1073 (mifepristone), a selective glucocorticoid receptor II (GRII) antagonist (not currently on the US market), has shown some promise i…”
BackgroundPsychiatric comorbidity in treatment-resistant depression
Alpert, J. E., & Lagomasino, I. T. (2001) · Cambridge University Press eBooks · doi:10.1017/cbo9780511666421.020 · Cited by 4
Research works printed but not linked: 11
- Richelson E., 2002, Psychopharmacol Bull., 36, 133
- Beck A., 1979, Cognitive Therapy of Depression. New York, NY: Guilford Press;
- Goldsmith SK., 2002, Institute of Medicine, National Academy of Sciences: Reducing Suicide, a National Imperative. Washington, DC: The National Academies Press;
- Liu B., 1996, Can Med Assoc J., 155, 519
- Schulberg HC., 1999, J Clin Psychiatry., 60, S19
- Pollock BG., 1999, J Clin Psychiatry., 60, S4
- Nierenberg AA., 1990, J Clin Psychiatry., 51, 39
- Thase ME., 1995, Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press;, 1081
- Paykel ES., 1994, Refractory Depression: Current Strategies and Future Directions. New York, NY: Wiley;, 3
- Keller M., 2001, J Am Acad Child Adolesc Psychiatry., 40, 762, 10.1097/00004583-200107000-00010 · DOI · Paper page
- Geddes JR., 2002, Depressive Disorders in Adults: Clinical Evidence. London, UK: BMJ Publishing Group;
Cited by
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Sexual Dysfunction, Depression, and the Impact of Antidepressants
Kennedy, S. H., & Rizvi, S. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819c76e9 · Cited by 338
Johnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321
Lekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R., Wisniewski, S. R., Manji, H., McMahon, F. J., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.026 · Cited by 284
Ricken, R., Ulrich, S., Schlattmann, P., & Adli, M. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.04.003 · Cited by 224
Metadata
- Authors
- Kupfer, D. J.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Kupfer, David J.
- ORCID
- Kupfer, David J.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2005-09-30
- Volume
- 7
- Issue
- 3
- Pages
- 191-205
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- PMC
- PMC3181740
- OpenAlex
- W16698172
- Cited by
- 69
- References
- 124
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 5 · 2023: 5 · 2022: 11 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 1 · 2017: 4 · 2016: 1 · 2015: 5 · 2014: 3 · 2013: 1 · 2012: 4
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH30915)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- depression, pharmacotherapy, antidepressants, depression severity assessment, suicidality, acute phase treatment, continuation treatment, maintenance therapy, recurrence risk, comorbidities, psychotic depression, bipolar depression, young patients, biomarkers, therapeutic target
- MeSH terms
- Adolescent, Antidepressive Agents, Brain, Child, Depression, Female, Humans, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.